PIK3CA and non-small cell lung carcinoma: In this study, isalpinin demonstrated in vitro anticancer activity by inhibiting the PI3K/Akt pathway through ATP-binding site interaction similar to alpelisib and by generating ROS, reflecting established NSCLC therapeutics [43,44].